At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
ADX-102 Ophthalmic Solution (0.5%) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
In Brief
A Phase 2 clinical trial evaluating ADX-102 Ophthalmic Solution (0.5%), ADX-102 Ophthalmic Solution (0.1%), and 1 other intervention for Dry Eye Syndromes. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartMay 2017
First PostedMay 2017
Primary CompletionJul 2017
TodayJul 2026
First PostedMay 22, 2017
Enrollment StartMay 15, 2017
Primary CompletionJul 6, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.1 years ago
Interventions
ADX-102 Ophthalmic Solution (0.5%)drug
ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
ADX-102 Ophthalmic Solution (0.1%)drug
ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
ADX-102 Ophthalmic Lipid Solution (0.5%)drug
ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.